Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nebulised heparin as a treatment for lung diseases: formulation challenges and pulmonary drug delivery strategies.

Lung·2026
Same author

IL-1β Pathway Inhibition in Asthma and COPD: Strong Biological Rationale, Disappointing Clinical Trials, and Emerging New Opportunities.

Lung·2026
Same author

The Platelet/Megakaryocyte Axis is Necessary for Allergic Sensitisation and Inflammatory Responses to House Dust Mite in the Lung.

Lung·2026
Same author

The Effect of the Novel Macrolide Glasmacinal (EP395) on Allergen-Induced Eosinophil Infiltration into the Lung.

Lung·2026
Same author

Pseudomonas aeruginosa infection exacerbates elastase induced lung damage: characterisation of a novel murine two-hit model of pulmonary infection.

Respiratory research·2025
Same author

Ensifentrine Plus a Long-Acting Muscarinic Antagonist in COPD: A Trifunctional Dual Bronchodilation Perspective.

Drugs·2025
Same journal

PD05, a novel neutrophil elastase inhibitor, mitigates LPS-induced acute lung injury in a preclinical model.

Pulmonary pharmacology & therapeutics·2026
Same journal

The preclinical discovery and development of depemokimab for severe eosinophilic asthma.

Pulmonary pharmacology & therapeutics·2026
Same journal

Synergistic induction of apoptosis in lung cancer cells via TOP2A targeting through combined dihydroartemisinin and chrysin treatment.

Pulmonary pharmacology & therapeutics·2026
Same journal

Evodiamine protects against lung ischemia-reperfusion injury by attenuating SYK-associated TLR4/NLRP3 inflammasome activation and ferroptosis-related injury signatures.

Pulmonary pharmacology & therapeutics·2026
Same journal

Evaluation of the effect of modulator therapies on medication complexity in adult cystic fibrosis patients.

Pulmonary pharmacology & therapeutics·2026
Same journal

Nicotinamide N-oxide alleviates sepsis-induced acute lung injury by inhibiting ferroptosis through activation of the SIRT1/AKT signalling pathway.

Pulmonary pharmacology & therapeutics·2026
See all related articles

Related Experiment Video

Updated: Jun 14, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Doxofylline: a "novofylline".

Clive P Page1

  • 1Sackler Institute of Pulmonary Pharmacology, King's College London, 5th Floor, Franklin Wilkins Building, 150 Stamford Street, Waterloo Campus, London SE1 9NH, UK. clive.page@kcl.ac.uk

Pulmonary Pharmacology & Therapeutics
|April 13, 2010
PubMed
Summary
This summary is machine-generated.

Doxofylline, a xanthine derivative, offers bronchodilator and anti-inflammatory benefits for lung diseases. It presents an improved safety profile compared to older xanthines like theophylline.

More Related Videos

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Related Experiment Videos

Last Updated: Jun 14, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Drug Development

Background:

  • Xanthines, including theophylline, have a long history in treating lung diseases.
  • Conventional xanthines possess a narrow therapeutic window and significant drug-drug interactions.
  • These limitations have reduced the clinical utility of xanthines with the advent of newer drug classes.

Purpose of the Study:

  • To discuss the evidence supporting doxofylline's efficacy in managing lung diseases.
  • To highlight doxofylline's potential as a bronchodilator and anti-inflammatory agent.
  • To compare doxofylline's therapeutic window and safety profile with conventional xanthines.

Main Methods:

  • Review of existing scientific literature and clinical studies on doxofylline.
  • Analysis of pharmacological properties, including bronchodilator and anti-inflammatory effects.
  • Comparative assessment of doxofylline versus theophylline regarding therapeutic index and interactions.

Main Results:

  • Doxofylline demonstrates both bronchodilator and anti-inflammatory activities.
  • Evidence suggests an improved therapeutic window for doxofylline compared to theophylline.
  • Doxofylline shows a potentially reduced profile of drug/drug interactions.

Conclusions:

  • Doxofylline represents a promising xanthine-based therapeutic option for lung diseases.
  • Its improved safety and efficacy profile warrants further clinical consideration.
  • Doxofylline may offer a valuable alternative for patients with respiratory conditions.